Are presently available insulin analogues clinically beneficial?

Diabetologia

Volumn 40, Issue SUPPL. 2, 1997, Pages

  Berger, M ^a   Heinemann, L ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

HbA(1c); Hypoglycaemia; Insulin analogues; Insulin dependent diabetes mellitus; Intensified insulin therapy; Quality of life

Indexed keywords

INSULIN DERIVATIVE;

CONFERENCE PAPER; DIABETES MELLITUS; DRUG USE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; GENETIC ENGINEERING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0030796921     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051416     Document Type: Conference Paper

References (42)

1. Berger M, Mühlhauser I (1995) Implementation of intensified insulin therapy: a European perspective. Diabet Med 12: 201-208
2. Heinemann L, Starke AAR, Hohmann A, Berger M (1992) Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res [Suppl] 26: 137-139
3. Berger M (1989) Towards more physiological insulin therapy in the 1990s. Diab Res Clin Pract 6: S25-S31
4. Berger M, Halban PA, Müller WA, Offord RE, Renold AE, Vranic M (1978) Mobilization of subcutaneously injected tritiated insulin in rats: effects of muscular exercise. Diabetologia 5: 133-140
5. Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P (1982) Absorption kinetics and biological effects of subcutaneously injected insulin preparations. Diabetes Care 5: 77-91
6. Brange J, Ribel U, Hansen JF et al. (1988) Monomeric insulins obtained by protein engeneering and their medical implications. Nature 333: 679-682
7. Brange J, Owens DR, Kang S, Vølund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13: 923-954
8. Brange J (1993) Design of insulin analogues for meal-related therapy. J Diab Compl 7: 106-112
9. Galloway JA, Chance RE (1994) Approaches to insulin analogues. In: Marshall SM, Home PD (eds) Diabetes Annual/8. Elsevier Science BV, Amsterdam, pp 277-297
10. B28) on meal-related plasma glucose excursions in Type 1 diabetic subjects. Diabetes Care 14: 571-577
11. Jørgensen LN, Dieriksen LH (1993) Preclinical studies of rapid-acting insulin analogues. In: Berger M, Gries FA (eds) frontiers in insulin pharmacology. Thieme, Stuttgart pp 110-115
12. Jörgensen S, Vaag A, Langjaer L, Hougaard P, Markussen J (1989) NovoSol Basal™: pharmacokinetics of a novel soluble long acting insulin analogue. BMJ 299: 415-419
13. 2(B31,B32)-human insulin with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 37: [Suppl] A 78 (abstract)
14. Markussen J, Havelund S, Kurtzhals P et al. (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39: 281-288
15. Heinemann L, Starke AAR, Heding L, Jensen I, Berger M (1990) Action profiles of fast onset insulin analogues. Diabetologia 33: 384-386
16. Heinemann L, Heise T, Jörgensen LN, Starke AAR (1993) Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 10: 535-539
17. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28),Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43: 396-402
18. Heinemann L, Kapitza C, Starke AAR, Heise T (1996) Time-action profile of the insulin analogue B28Asp. Diabet Med 13:683-684
19. Torlone E, Fanelli C, Rambotti AM et al. (1994) Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia 37:713-720
20. Jacobs MAJM (1995) Meal related insulin substitution. Academisch Proefschrift, Vrije Universiteit Amsterdam
21. Tuominen JA, Karonen S-L, Melamies L, Bolli G, Koivisto VA (1995) Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 38: 106-111
22. Heinemann L, Heise T, Wahl C et al. (1996) Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients using the rapid acting insulin analogue [Lys(B28), Pro(B29)]. Diabet Med 13: 625-629
23. Lutterman JA, Pijpers E, Netten PM, Jørgensen LN (1993) Glycaemic control in IDDM patients during one day with injection of human insulin or the insulin analogues insulin X14 and insulin X14(+ Zn). In: Berger M, Gries FA (eds): Frontiers in insulin pharmacology. Thieme, Stuttgart, pp 102-109
24. Wiefels K, Kuglin B, Hübinger A, Jørgensen LN, Gries FA (1993) Insulin kinetics and dynamics in insulin dependent diabetic patients after injections of human insulin or the insulin analogues X14 and X14 + Zn. In: Berger M, Gries FA (eds): Frontiers in insulin pharmacology. Thieme, Stuttgart, pp 97-101
25. Nielsen FS, Jørgensen LN, Ipsen M, Vooldsgaard AI, Parving HH (1995) Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38: 592-598
26. Jörgens V, Grüsser M, Bott U, Mühlhauser I, Berger M (1993) Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia 36: 99-105
27. Mühlhauser I, Bott U, Overmann H et al. (1995) Liberalized diet in patients with type 1 diabetes. J Intern Med 237:591-597
28. Trautmann ME (1994) Ergebnisse der weltweit durchgeführten Studien mit dem schnell-wirksamen Insulinanalogon LYSPRO. Diabetes Stoffw 3 [Suppl]: 128 (Abstract)
29. Anderson JH, Brunelle RL, Vignati L (1995) Insulin lispro compared to regular insulin in a crossover study involving 1057 patients with type 1 diabetes. Diabetes 44 [Suppl 1]: 228A (Abstract)
30. Brunelle RL, Anderson JH, Vignati L (1995) Insulin lispro improves postprandial control in a large crossover study in patients with type II diabetes. Diabetologia 38 [Suppl 1]: A 3 (Abstract)
31. Pieber TR, Feinböck C, Rabensteiner D, Weitgasser R, Ristic S (1995) Lispro insulin analog in twice-a-day insulin treatment. Diabetologia 38 [Suppl 1]: A3 (Abstract)
32. Garg SK, Carmain JA, Braddy KC et al. (1996) Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 13:47-52
33. Trautmann ME, Anderson JH (1995) Insulin lispro facilitates diabetes management. Proceedings of the III St. Vincent Meeting. Athens 1995. Hormone Metab Res Abstract [Suppl 1] p 67
34. Pfützner A, Küstner E, Forst T et al. on the behalf of the German Insulin Lispro/IDDM study group (1996) Intensive insulin therapy with insulin lispro in patients with type I diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104: 25-30
35. Anderson JH, Brunelle RL, Pfützner A, Trautmann ME, Vignati L (1996) Reduced frequency of hypoglycemia without loss of glycemic control. Diabetes 45 [Suppl 2]: 59 A (Abstract)
36. Zinman B, Chiasson JL, Tildesly H, Tsui E, Strack T (1996) Insulin lispro in CSII: results of a double-blind, cross-over study. Diabetes 45 [Suppl 2]: 28A (Abstract)
37. Pein M, Hinseimann C, Pfützner A, Dreyer M (1996) Catheter disconnection in type-1 diabetic patients treated with CSII. Comparison of insulin lispro and human regular insulin. Diabetologia 39 [Suppl 1]: A223 (Abstract)
38. Rowe R, Anderson JH, Gale E (1996) A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen. Diabetes 45 [Suppl 2]: 71 A (Abstract)
39. Berger M, Jörgens V (1995) Praxis der Insulintherapie. (1st edn 1983) 5th edn Springer, Berlin Heidelberg New York
40. Heinemann L (1995) Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 12: 449-450
41. Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Armqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34: 307-313
42. Ottensen JL, Nilsson P, Jami J et al. (1994) The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37: 1178-1185